CLEC9A抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue lysate, Primary antibody: P05636(CLEC9A Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 20 seconds    

  
  

CLEC9A (C-type lectin domain containing 9A), also known as DNGR-1. is a type II transmembrane protein belonging to the C-type lectin receptor family. It is primarily expressed on a subset of dendritic cells (DCs), particularly the CD8α⁺/CD103⁺ conventional DCs in mice and their equivalents in humans. Discovered in 2008. CLEC9A functions as a pattern recognition receptor that senses cytoskeletal filaments (e.g., F-actin) exposed upon cell necrosis, facilitating the uptake and cross-presentation of dead cell-associated antigens to CD8⁺ T cells. This unique role positions CLEC9A as a critical mediator in bridging innate and adaptive immunity, particularly in anti-tumor and antiviral responses.

CLEC9A antibodies are valuable tools for targeting DC subsets to enhance antigen-specific immune responses. They are often engineered as monoclonal antibodies (mAbs) or conjugated to antigens, vaccines, or therapeutic payloads (e.g., nanoparticles or fusion proteins) to direct cargo specifically to CLEC9A⁺ DCs. Preclinical studies highlight their potential in cancer immunotherapy, where CLEC9A-targeted strategies boost T cell priming and antitumor efficacy. Additionally, these antibodies aid in studying DC biology, including receptor trafficking, signaling, and antigen-processing pathways. Despite promise, challenges remain in optimizing specificity and minimizing off-target effects. Research continues to explore CLEC9A's structural interactions and therapeutic applications in vaccines, autoimmune diseases, and infectious diseases.